Compare FOXX & CNSY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FOXX | CNSY |
|---|---|---|
| Founded | 2017 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.3M | 20.6M |
| IPO Year | 2025 | 2016 |
| Metric | FOXX | CNSY |
|---|---|---|
| Price | $2.51 | $1.56 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $27.75 |
| AVG Volume (30 Days) | 4.8K | ★ 162.8K |
| Earning Date | 09-28-2026 | 10-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 87.61 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $52,584,432.00 | $5,213,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $414.61 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.71 | $1.64 |
| 52 Week High | $7.90 | $4.03 |
| Indicator | FOXX | CNSY |
|---|---|---|
| Relative Strength Index (RSI) | 47.16 | 20.90 |
| Support Level | $2.39 | N/A |
| Resistance Level | $2.69 | $3.28 |
| Average True Range (ATR) | 0.17 | 0.18 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 67.31 | 8.18 |
Foxx Development Holdings Inc is a consumer electronics and integrated Internet-of-Things (IoT) solution company catering to both retail and institutional clients. With robust research and development capabilities and a strategic commitment to cultivating long-term partnerships with mobile network operators, distributors, and suppliers. Its products include tablets, smartphones, wearables, and other high-quality communication terminals. The company's current revenue stream is derived from the sales of tablets and smartphones.
Cerenome Inc is a CNS oncology company advancing an integrated platform that combines precision diagnostics, targeted therapeutics, and artificial intelligence to improve outcomes for patients with central nervous system cancers. The Company's CNSide Diagnostics platform supports the detection, molecular characterization, and longitudinal monitoring of CNS cancers through cerebrospinal fluid-based testing. Its therapeutic platform, REYOBIQ (rhenium Re186 obisbemeda), is being evaluated in clinical trials for leptomeningeal metastases, recurrent glioblastoma, and pediatric brain cancers. The data & artificial intelligence platform is designed to integrate diagnostic, molecular, imaging, and clinical data into actionable insights that support precision oncology and therapeutic innovation.